Science Corporation Closes $230 Million Series C to Accelerate Commercialization of Its PRIMA BCI Retinal Implant, the World’s Most Advanced Vision Restoration Technology

Syndicate Composed of Leading Investors Including Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital

Company Expands PRIMA Clinical Trials to Include Additional Retinal Diseases

ALAMEDA, Calif--(BUSINESS WIRE)--Science Corporation, the pioneering full-stack neural engineering company focused on restoring and extending life, today announced the close of an oversubscribed $230 million Series C financing round. The round includes participation from a distinguished group of investors, including Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital, among others. This financing brings the company’s total capital raised to approximately $490 million since its founding in 2021.

The funds will accelerate the commercialization of Science’s brain-computer interface (BCI) retinal implant, PRIMA. In clinical trials, PRIMA was the only treatment to successfully restore form vision to patients blinded by late-stage macular degeneration. The PRIMA trial results were featured in The New England Journal of Medicine (NEJM) and on the cover of Time.

The capital will also support the expansion of the company’s research, manufacturing, and operational infrastructure, as well as the continued advancement of its state-of-the-art Biohybrid neural interface technology and Vessel perfusion platform.

With the expected commercial launch of PRIMA later this year in Europe, Science will be the first BCI company with a vision restoration product in the market. Science has rapidly emerged as a leading neural engineering company, with a growing portfolio designed to address significant unmet clinical needs while advancing the frontier of BCIs. The Series C round comes amid strong investor demand, reflecting confidence in the company’s scientific depth, executive leadership, and long-term vision to shape the future of medicine.

“We are building a company which will offer patients hope beyond the limitations of traditional medicine,” said Max Hodak, cofounder and CEO of Science. “By engaging the brain directly as an information processing organ, we are able to achieve much greater effect sizes and drive unprecedented clinical impact. We are deeply committed to research and new technologies that can provide treatment options where none existed before – and which will fundamentally change and improve lives.”

“The strength and caliber of this syndicate reflects both the urgency of the problems we are addressing and the credibility of our execution so far,” said Darius Shahida, Science’s Chief Strategy Officer. “With this capital, we are focused on commercialization and delivering real-world clinical impact. Our imperative is to become the first BCI company to scale and achieve profitability.”

Expansion of clinical trials

The company also announced the expansion of its PRIMA clinical trial program to include other retinal diseases, such as Stargardt disease and retinitis pigmentosa. These conditions are the leading causes of inherited retinal vision loss in young adults, affecting 1 in 10,000 and 1 in 4,000 people, respectively. The initial trial will be conducted by Dr. Matthew Simunovic, MB BChir, PhD, a leader in the field of retinal disease therapy and pioneer in prosthetic vision research, at the Sydney Eye Hospital in Australia.

Results from the earlier landmark PRIMA clinical trial in Europe demonstrated that the implant could restore functional central vision, effectively working as artificial photoreceptors in the retina. The trial evaluated the PRIMA system in 38 blinded patients with advanced dry age-related macular degeneration. The peer-reviewed original paper published by the NEJM showed that 80% of patients demonstrated meaningful improvement of visual acuity and were able to read letters, numbers, and words.

Following these unprecedented results, Science submitted a CE mark application to the European Union. In parallel, the company has applied to the U.S. Food and Drug Administration for regulatory approval.

About Science Corporation

Science Corporation is a vertically integrated, full stack neural engineering company. Our mission is to restore and extend life by transcending the limits of biology. We are developing advanced brain-computer interface technologies and devices to address critical unmet medical needs and, longer term, to transform the human condition through neural engineering and advanced perfusion technology. Science is headquartered in Alameda, Calif. For more information please visit: www.science.xyz.